| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5656457 | HPB | 2017 | 8 Pages |
Abstract
TACE is a safe treatment for a highly selected population of HCC patients with PVT. Despite worse survival rates compared to PVB thrombosis, PVT in the MPV should not be considered an absolute contraindication to TACE.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Jack P. Silva, Nicholas G. Berger, Susan Tsai, Kathleen K. Christians, Callisia N. Clarke, Harveshp Mogal, Sarah White, William Rilling, T. Clark Gamblin,